InvestSMART

Clarity Pharmaceuticals Ltd (ASX: CU6) - Announcements

Current share price for CU6 : $1.770 0.065 (3.54%)+

ASX company news and announcements for Clarity Pharmaceuticals Ltd (CU6) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Clarity Pharmaceuticals Ltd (CU6) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Clarity Pharmaceuticals Ltd (CU6), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Clarity Pharmaceuticals Ltd (CU6)

Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
$660 Change of Director's Interest Notice - Parker 22 Apr 2026 4:23PM $2.930 $1.770 fallen by 39.59%
$660 Clarity signs a Commercial Manufacturing Agreement 14 Apr 2026 8:33AM $3.130 $1.770 fallen by 43.45%
$660 Ceasing to be a substantial holder 10 Apr 2026 5:01PM $3.180 $1.770 fallen by 44.34%
$660 Becoming a substantial holder 9 Apr 2026 4:12PM $3.140 $1.770 fallen by 43.63%
$660 Final Director's Interest Notice - Biggin 9 Apr 2026 9:42AM $3.250 $1.770 fallen by 45.54%
$660 Director Appointment/Resignation 9 Apr 2026 8:57AM $3.250 $1.770 fallen by 45.54%
$660 Notification regarding unquoted securities - CU6 7 Apr 2026 11:22AM $3.180 $1.770 fallen by 44.34%
$660 Cleansing Notice 31 Mar 2026 5:15PM $3.100 $1.770 fallen by 42.90%
$660 Application for quotation of securities - CU6 31 Mar 2026 5:11PM $3.100 $1.770 fallen by 42.90%
$660 Co-PSMA data published in the European Urology journal 31 Mar 2026 9:20AM $3.030 $1.770 fallen by 41.58%
$660 Becoming a substantial holder 26 Mar 2026 8:16AM $3.440 $1.770 fallen by 48.55%
$660 Clarity signs a large-scale Manufacturing Supply Agreement 25 Mar 2026 9:24AM $3.070 $1.770 fallen by 42.35%
$660 Co-PSMA data presented 17 Mar 2026 9:40AM $3.620 $1.770 fallen by 51.10%
$660 Cleansing Notice 11 Mar 2026 12:34PM $3.820 $1.770 fallen by 53.66%
$660 Application for quotation of securities - CU6 11 Mar 2026 12:28PM $3.800 $1.770 fallen by 53.42%
$660 AMPLIFY trial - Target number of participants achieved 10 Mar 2026 9:03AM $3.290 $1.770 fallen by 46.20%
$660 Notification regarding unquoted securities - CU6 2 Mar 2026 11:41AM $3.350 $1.770 fallen by 47.16%
$660 Half Year Accounts 27 Feb 2026 9:51AM $3.600 $1.770 fallen by 50.83%
$660 Half Yearly Report and Accounts 27 Feb 2026 9:48AM $3.600 $1.770 fallen by 50.83%
$660 SECuRE trial update 23 Feb 2026 9:00AM $3.510 $1.770 fallen by 49.57%
$660 Co-PSMA abstract released 16 Feb 2026 9:42AM $2.860 $1.770 fallen by 38.11%
$660 Change in substantial holding 12 Feb 2026 5:27PM $3.030 $1.770 fallen by 41.58%
$660 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 10:50AM $3.160 $1.770 fallen by 43.99%
$660 SECuRE trial to continue with no modifications to protocol 15 Jan 2026 9:46AM $3.600 $1.770 fallen by 50.83%
$660 Notification of cessation of securities - CU6 7 Jan 2026 4:45PM $3.920 $1.770 fallen by 54.85%

51 - 75 of 531 results

Page 3 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.